Improving the quality of life for patients with atrial fibrillation
The BRACE-AFib study is investigating whether switching from beta blockers to a calcium channel blocker can improve the quality of life of patients with atrial fibrillation.
Background
Atrial fibrillation is a common cardiac arrhythmia that can lead to an accelerated heartbeat. Effective control of the heart rate is crucial for the well-being of affected patients. Most commonly, beta blockers are prescribed to control the heart rate although various other drugs are available.
Many patients receiving beta blockers report side effects such as fatigue and dizziness, which can affect their quality of life. Non-dihydropyridine calcium channel blockers (NDCCs) are a promising alternative as they may be associated with fewer side effects. So far, there is only limited evidence that allows a direct comparison of these two treatment options.
Aim
The aim of our study is to investigate whether switching from beta blockers to an NDCC can improve the quality of life of patients with atrial fibrillation. By comparing the two treatment options, we hope to identify a treatment that not only controls the heart rate but also promotes general well-being.
BRACE-AFib Study
Beta-blocker Replacement And Calcium channel blockers Evaluation in Atrial Fibrillation
Principal Investigators
PD Dr. med. Patrick Badertscher, University Hospital Basel, DKF Research Group Leader
Prof. Dr. med. Michael Kühne, University Hospital Basel, DKF Research Group Leader
Study design
Multicentre, double-blind, randomised-controlled superiority study
Study centers
9 centers in Switzerland
Number of planned study participants
272
Project duration
5 years
DKF support
Methodological Counsulting, Data Analysis/Statistics, Data Management, Data Science, Consulting on Patient & Public Involvement
Funding
SNSF IICT, Call 2024
Does the quality of life of patients with atrial fibrillation improve when beta blocker therapy is replaced by calcium channel blocker therapy?
Study methodology
Multicentre, double-blind, randomised controlled superiority trial
The Swiss Atrial Fibrillation Cohort (Swiss AF) provides the data basis for this study.
Significance of the study
By comparing beta blockers and NDCC for the treatment of atrial fibrillation, we want to identify a therapy that improves the quality of life of those affected. With millions of people worldwide suffering from atrial fibrillation this study is both timely and potentially groundbreaking for improved care. This study not only fills a significant gap in knowledge but also focuses on the experiences of patients.
July 2025